clinical trial · NCT07585097
A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
Alagille Syndrome
brief summary
This study will collect information from patients with ALGS who are using odevixibat in their daily lives. Odevixibat is a medication that helps patients with ALGS, a rare disease that affects the liver and causes itching. The main aim of this study is to observe the long-term, everyday safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.
started
Jul 10, 2026
primary completion
Sep 30, 2031
completion
Sep 30, 2031
last updated
Aug 3, 2026
official title
Prospective Non-Interventional Study Evaluating the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol